Teva MS Drug Patent Backed By UK High Court In Mylan Row

Law360, New York (July 29, 2013, 4:46 PM EDT) -- The U.K. High Court of Justice on Monday affirmed the validity of a Teva Pharmaceutical Industries Ltd. patent for its multiple sclerosis drug Copaxone, ruling the patent would be infringed by generic versions of the drug being developed by Mylan Laboratories Inc.

In a unanimous decision, the appellate court refused a bid by Mylan's Generics (UK) Ltd. unit to revoke Teva's European Patent (UK) 762,888. The decision affirms a ruling issued last year by Justice Richard David Arnold, the head of the U.K.'s patents court....
To view the full article, register now.